Generated August 31, 2026 at 12:39 PM ET
· Covers August 31 trading day
· 10 of 54 ready 8-Ks selected
· AI-assisted overview
Today's filings featured major M&A activity, with SLB announcing a $3.4B cash acquisition of Kelvion and Aon agreeing to buy USI for $17.0B. Several companies reported regulatory and leadership developments: Innventure accelerated its CEO transition amid a securities class action, Northann received a delisting notice from NYSE American, and Cadrenal gained FDA alignment on a Phase 3 endpoint. Karyopharm submitted an sNDA for XPOVIO, while USA Rare Earth shareholders approved a share issuance for its merger. Leadership changes included Zedge naming a new CEO and raising $7.5M, and Expion360 appointing a CFO, while Energy & Water Development's chairman resigned alleging misconduct.
leadership
negative
materiality 0.85
August 31, 2026, 8:19 AM ET
Innventure accelerates CEO transition to Grieco, faces securities class action
- CEO Gregory Haskell retires effective Sept 1, 2026; Dr. William Grieco succeeds as CEO and Class I director, accelerated from Oct 1.
- CFO David Yablunosky to be replaced; search for successor ongoing, no replacement named yet.
- Michael Otworth resigns as Executive Chairman; Bruce Brown appointed independent Chairman effective Aug 28, 2026.
regulatory
negative
materiality 0.80
August 31, 2026, 6:25 AM ET
Northann receives NYSE American delisting notice; requests oral hearing
- NYSE Regulation notified Northann on Aug 21, 2026 of intent to delist common stock from NYSE American.
- Company requested oral hearing before Listings Qualifications Panel on Aug 28, 2026 to review determination.
- Auditor LAO Professionals resigned June 8, 2026; Audit Committee appointed TQ International, PLLC on Aug 26, 2026.
M&A
positive
materiality 1.00
August 31, 2026, 6:58 AM ET
SLB to acquire Kelvion for ~$3.4B cash plus $0.7B debt, expanding data center business
- Acquires Kelvion from Apollo and Triton for ~$3.4B cash plus ~$0.7B debt assumed; ~11x 2026E EBITDA pre-synergies.
- Kelvion 2026E revenue $2.3-2.4B, adj EBITDA $350-400M; data center revenue $1.2-1.3B.
- Expects ~$120M annual EBITDA synergies within 3 years; accretive to EPS and FCF per share in first 12 months post-close.
CVKD
Cadrenal Therapeutics, Inc.
regulatory
positive
materiality 0.75
August 31, 2026, 8:29 AM ET
Cadrenal gets FDA alignment on Phase 3 endpoint for CAD-1005 in HIT
- FDA Type D meeting July 28, 2026; agreed on primary endpoint definition for worsening HIT through Day 14 or discharge.
- Primary endpoint: proportion of SRA+ participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
- FDA agreed to placebo control with standard anticoagulation for both CAD-1005 and placebo arms.
M&A
positive
materiality 0.95
August 31, 2026, 6:37 AM ET
Aon to acquire USI for $17.0B cash, creating premier U.S. middle-market platform
- Aon signs $17.0B cash deal for USI; net $16.7B after ~$278M tax attributes, ~14.5x synergized EBITDA.
- Expects $395M annual run-rate net adjusted EBITDA impact from revenue and cost synergies; accretive to adjusted EPS in 2028.
- USI is 10th largest U.S. broker with ~$3B revenue, 10,500+ staff, ~200 offices; expands Aon's E&S access.
KPTI
Karyopharm Therapeutics Inc.
regulatory
positive
materiality 0.70
August 31, 2026, 8:08 AM ET
Karyopharm submits sNDA for XPOVIO+ruxolitinib in myelofibrosis; seeks Priority Review
- On Aug 31, 2026, submitted sNDA to FDA for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, requesting Priority Review.
- FDA decision on filing acceptance and review timelines expected in Q4 2026 after 60-day filing review period.
- Submission based on Phase 3 SENTRY trial data, including promising overall survival signal and positive benefit-risk profile.
USAR
USA Rare Earth, Inc.
M&A
positive
materiality 0.85
August 31, 2026, 6:37 AM ET
USA Rare Earth shareholders approve share issuance for Serra Verde merger
- Approved issuance of 126,849,307 common shares in merger with Serra Verde Rare Earths (SVRE Holdings).
- Vote: 108,248,297 for, 1,403,269 against, 16,879,393 abstentions on share issuance proposal.
- Adjournment proposal also approved: 94,439,941 for, 15,025,106 against, 17,065,912 abstentions.
—
Energy & Water Development Corp
leadership
negative
materiality 0.80
August 31, 2026, 10:12 AM ET
Chairman Hofmeier resigns alleging CEO misconduct; two new directors appointed
- Ralph Max Hofmeier resigned as Chairman and director on Aug 26, 2026, citing disagreement with CEO and alleging unlawful activities and fiduciary breaches.
- Company disputes allegations, says they are unsubstantiated; no independent investigation or adjudication has occurred.
- Dale Johnson III appointed director effective Aug 27, 2026; Luis R. Vera Morales appointed to new board seat effective Aug 29, 2026.
other material
positive
materiality 0.85
August 31, 2026, 6:31 AM ET
Zedge names Morris Berger CEO, raises $7.5M from insiders for DataSeeds.AI
- Morris Berger (ex-CEO of Zeno Media, IDT Entertainment) becomes Zedge CEO Oct 1, 2026; Jonathan Reich moves to President/COO.
- Insider investment of ~$7.5M led by Vice Chairman Howard Jonas; 90% warrant coverage, 5-yr term, exercise price 110% of purchase price.
- DataSeeds.AI expands: first six-figure order fulfilled in FY2026, first model-evaluation deal signed; targeting AI data market growing to $16.3B by 2033.
leadership
positive
materiality 0.60
August 31, 2026, 8:05 AM ET
Expion Energy appoints Robert Winspear CFO, Marc Jarvis to board; annual meeting Nov 4
- Robert Winspear named CFO, Secretary, Treasurer effective Aug 25, 2026; base salary $285k, rising to $300k after timely 10-K filing.
- Winspear receives 30,000 RSUs and conditional 15,000 stock options; vesting 25% on first anniversary, then quarterly.
- Former CFO Shawna Bowin remains as VP Finance through ~Oct 31, 2026 to assist transition.